These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 3409505)

  • 1. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries.
    Golino P; Buja LM; Ashton JH; Kulkarni P; Taylor A; Willerson JT
    Circulation; 1988 Sep; 78(3):701-11. PubMed ID: 3409505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries.
    Yao SK; Ober JC; McNatt J; Benedict CR; Rosolowsky M; Anderson HV; Cui K; Maffrand JP; Campbell WB; Buja LM
    Circ Res; 1992 Jan; 70(1):39-48. PubMed ID: 1727687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A2/prostaglandin H2 receptor antagonists.
    Ashton JH; Schmitz JM; Campbell WB; Ogletree ML; Raheja S; Taylor AL; Fitzgerald C; Buja LM; Willerson JT
    Circ Res; 1986 Nov; 59(5):568-78. PubMed ID: 3542279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses.
    Ashton JH; Ogletree ML; Michel IM; Golino P; McNatt JM; Taylor AL; Raheja S; Schmitz J; Buja LM; Campbell WB
    Circulation; 1987 Oct; 76(4):952-9. PubMed ID: 3652429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators.
    Golino P; Ashton JH; Buja LM; Rosolowsky M; Taylor AL; McNatt J; Campbell WB; Willerson JT
    Circulation; 1989 Jan; 79(1):154-66. PubMed ID: 2910540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboxane A2 and serotonin mediate coronary blood flow reductions in unsedated dogs.
    Eidt JF; Ashton J; Golino P; McNatt J; Buja LM; Willerson JT
    Am J Physiol; 1989 Sep; 257(3 Pt 2):H873-82. PubMed ID: 2782444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
    Golino P; Ashton JH; Glas-Greenwalt P; McNatt J; Buja LM; Willerson JT
    Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.
    Eidt JF; Allison P; Noble S; Ashton J; Golino P; McNatt J; Buja LM; Willerson JT
    J Clin Invest; 1989 Jul; 84(1):18-27. PubMed ID: 2661588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of nitroglycerin and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: further evidence for thromboxane A2 and serotonin as mediators of coronary artery vasoconstriction in vivo.
    Golino P; Buja LM; Yao SK; McNatt J; Willerson JT
    J Am Coll Cardiol; 1990 Mar; 15(3):718-26. PubMed ID: 2105989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis.
    Yao SK; Benedict CR; Rosolowsky M; McNatt J; Falinska B; Campbell WB; Buja LM; Willerson JT
    J Mol Cell Cardiol; 1991 Apr; 23(4):473-82. PubMed ID: 1942081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin S2 and thromboxane A2-prostaglandin H2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries.
    Ashton JH; Golino P; McNatt JM; Buja LM; Willerson JT
    J Am Coll Cardiol; 1989 Mar; 13(3):755-63. PubMed ID: 2521875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries.
    Yao SK; Ober JC; Gonenne A; Clubb FJ; Krishnaswami A; Ferguson JJ; Anderson HV; Gorecki M; Buja LM; Willerson JT
    Circ Res; 1993 Nov; 73(5):952-67. PubMed ID: 8403265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation.
    Golino P; Ambrosio G; Ragni M; Pascucci I; Triggiani M; Oriente A; McNatt J; Buja LM; Condorelli M; Chiariello M
    Circulation; 1993 Sep; 88(3):1205-14. PubMed ID: 8353882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries.
    Bush LR; Campbell WB; Kern K; Tilton GD; Apprill P; Ashton J; Schmitz J; Buja LM; Willerson JT
    Circ Res; 1984 Nov; 55(5):642-52. PubMed ID: 6488486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
    Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations.
    Yao SK; Rosolowsky M; Anderson HV; Golino P; NcNatt JM; De Clerck F; Buja LM; Willerson JT
    J Am Coll Cardiol; 1990 Sep; 16(3):705-13. PubMed ID: 2143767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay between platelet-derived 5-hydroxytryptamine and arachidonic acid metabolites limits the thrombolytic efficacy of streptokinase against canine platelet-rich coronary thrombosis.
    Vandeplassche G; Hermans C; Van Dael L; Wouters L; De Clerck F
    J Cardiovasc Pharmacol; 1993 Jan; 21(1):56-69. PubMed ID: 7678680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury.
    Willerson JT; Eidt JF; McNatt J; Yao SK; Golino P; Anderson HV; Buja LM
    J Am Coll Cardiol; 1991 May; 17(6 Suppl B):101B-110B. PubMed ID: 2016468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukocyte and platelet-derived factors augment canine coronary constriction to serotonin.
    Cappelli-Bigazzi M; Lamping KG; Nuno DW; Harrison DG
    Am J Physiol; 1990 Oct; 259(4 Pt 2):H1161-70. PubMed ID: 2171364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposome-bound prostaglandin E1 often prevents cyclic flow variations in stenosed and endothelium-injured canine coronary arteries.
    Willerson JT; Yao SK; McNatt J; Cui K; Anderson HV; Swensen C; Ostro M; Buja LM
    Circulation; 1994 Apr; 89(4):1786-91. PubMed ID: 8149544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.